Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | QoL with CAR T-cell therapy for multiple myeloma

Michel Delforge • 16 Dec 2020
ASH 2020
Multiple Myeloma CAR-T Ciltacabtagene autoleucel
CARTITUDE-1

Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses quality of life (QoL) outcomes for patients receiving chimeric antigen receptor (CAR) T-cell therapy, highlighting results from the Phase Ib/II CARTITUDE-1 trial (NCT03548207). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Michel Delforge, MD, PhD, has participated in advisory boards for Amgen, Celgene-BMS, GSK, Janssen, Takeda and Sanofi; and has received research grants from Amgen, Celgene, Janssen, Takeda and Sanofi.

More from Michel Delforge

2:20
HRQoL in heavily pretreated patients with MM treated with ide-cel or standard regimens in KarMMa-3
Michel Delforge • 10 Dec 2023
2:16
Moving CAR-T therapy into the frontline setting in myeloma: insights into CARTITUDE-5 & CARTITUDE-6
Michel Delforge • 4 Oct 2023
1:50
How might inequalities in access to CAR-T therapy for multiple myeloma be addressed?
Michel Delforge • 4 Oct 2023
8:28
Treatment selection for patients with multiple myeloma at first relapse and beyond
Michel Delforge • 4 Oct 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals